HIV-Associated Tuberculosis 2012
1National Institute for Medical Research, Mill Hill, London NW7 1AA, UK; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, Cape Town 7701, South Africa
2Department of Infectious Diseases, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Department of Medicine, University of Cambridge, Cambridge CB2 1TN, UK
3Department of Environmental and Occupational Health, Center for Global Public Health, School of Public Health, UMDNJ, NJ, USA
4Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7701, South Africa
HIV-Associated Tuberculosis 2012
Description
Tuberculosis is an important public health problem and remains a leading cause of death in low- and middle-income countries, with an estimated 9.27 million new cases and 1.7 million deaths worldwide in 2007. HIV infection is the greatest risk factor for developing TB. The devastating association between HIV and TB means that 1.37 million of the new TB cases were amongst HIV-infected people and one out of four TB deaths was HIV related in 2007. The risk of TB is increased during all stages of HIV infection from about 10% over a lifetime (in HIV-uninfected individuals) to as high as 30% per annum in patients with advanced HIV. These circumstances define the analysis of the immune response to TB in the context of HIV infection as a pressing research priority. With these facts in mind, the focus of our special issue will be the immunology of HIV-associated tuberculosis. We invite authors to present original research articles that will reflect and stimulate the continuing efforts to elucidate the protective and pathogenic immune mechanisms in adults and children affected by both HIV and TB. The topics to be covered include, but are not limited to:
- Epidemiology (related to the combined effect of HIV and TB)
- Interaction between host and pathogens (effect of acute HIV infection on TB-specific immune responses, effect of TB infection on HIV progression, immune reconstitution inflammatory syndrome, and development of TB during antiretroviral therapy)
- Diagnosis (immunological assays for TB in HIV-infected people; biomarkers to define the risk of TB in HIV-infected people)
- Treatment advances (TB treatment shortening regimes in the context of HIV infection and problems with drug interactions)
- Nonvaccination-based prevention strategies (isoniazid preventive therapy in the context of antiretroviral treatment; preventing mother-to-child transmission of HIV infection in the context of TB; microbicides in the context of TB)
- Vaccination strategies (safety and efficacy of novel TB vaccines in HIV-infected people)
- Animal models for understanding the combined effect of HIV and TB (e.g., studies on primate models dually infected with TB and SIV)
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: